Glancy Prongay & Murray LLP, a leading securities fraud law firm, announces an investigation into Sema4 Holdings Corp. (SMFR, SMFRW) on behalf of investors

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has initiated an investigation on behalf of Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors regarding the Company’s possible violations of federal securities laws.

If you have suffered a loss on your Sema4 investments or would like to inquire about possible claims to recover your loss under federal securities laws, you can submit your details at www.glancylaw.com/cases/sema4 -holdings-corp/. You may also contact Charles H. Linehan of GPM at 310-201-9150, toll-free at 888-773-9224, or by email at [email protected] to learn more about your rights.

On July 22, 2021, CM Life Sciences, Inc., a special purpose acquisition company, completed its business combination with Mount Sinai Genomics, Inc., and the combined public entity was renamed Sema4.

Less than a year later, on June 14, 2022, Sema4 announced the departure of its chief financial officer.

Then, on August 15, 2022, after the market closed, Sema4 announced changes to its research and development leadership team, including that its founder was leaving the organization and stepping down as president and head of R&D. The company also revealed that it was eliminating about 13% of its workforce as part of a series of corporate restructurings and realignments. Additionally, Sema4 lowered its fiscal year 2022 revenue guidance to $245 million to $255 million from its previous guidance of $305 million to $315 million.

On this news, Sema4 stock fell $0.80, or 33.3%, to close at $1.60 per share on August 16, 2022, hurting investors.

Follow us for updates on LinkedIn, Twitteror facebook.

Notice of denunciation: People with nonpublic information regarding Sema4 should consider their options to help the investigation or take advantage of the SEC’s whistleblower program. Under this program, whistleblowers who provide original information can receive rewards of up to 30% of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected]

About GPM

Glancy Prongay & Murray LLP is a leading law firm representing investors and consumers in securities litigation and other complex class actions. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 report. In 2018, GPM was ranked among the top five law firms for the number of securities class action settlements and among the top six law firms for the full amount of the settlements. With four offices across the country, nearly 40 GPM attorneys have won groundbreaking decisions and recovered billions of dollars for investors and consumers in securities, antitrust, consumer and employment class action lawsuits. GPM attorneys have handled cases covering a wide range of corporate misconduct, including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings advice and forward-looking statements, audit misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities matters involving nearly every industry and sector of the capital markets, including energy, consumer discretionary, consumer staples, real estate and REITs, financials, insurance, information technology, healthcare, biotechnology, cryptocurrency, medical devices. , and much more. GPM’s past successes have been widely covered by major industry news and publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reutersthe Associated press, Barrons, Investor’s Business Daily, Forbesand Silver.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.